Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Basic valuations and simple math put this stock at around $14-16/share. Clinical biotech’s tend to be values 3x peak sales. With just the RSV vaccine sales at around $1.5 Billion that puts NVAX market cap at about 4.5 billon, 4,500,000,000 divided by 279,000,000 shares in the float comes out to be $16/share. This could see some huge gains!!!
They better cover if they don’t wanna lose their ass
BOOM $2
Everyone wants in under $2 only a few left!
Here comes the $2 break!
1 mil volume in the first minute!
Novavax provided an update on the status of its Phase 3 Respiratory Syncytial Virus vaccine for Infants Via Maternal Immunization clinical trial, dubbed the "Prepare" trial. Novavax pointed out that an informational analysis was performed in the fourth quarter of 2017, and targeted an efficacy threshold against the primary endpoint at day 90 of more than 40%. In December, the Data Safety Monitoring Board statistician performed an unblinded analysis and communicated that the RSV F vaccine "successfully met" the criteria, the company highlighted in the slides. Importantly, Novavax stated that the informational analysis indicated that its RSV F Vaccine is efficacious, and that Phase 3 enrollment should yield pivotal efficacy data by the fourth quarter of 2018 and the first quarter of 2019. The company expects it to be the first licensed RSV vaccine, with an estimated global peak revenue of over $1.5B.
Read more at:
https://thefly.com/landingPageNews.php?id=2665398
NVAX the only RSV vaccine in phase 3 trials! With initial positive results! Now I see why they raised the price target to $10
B. Riley FBR analyst George Zavoico raised his price target for Novavax nearly five-fold to $10 after the company announced more details about an informational analysis of Prepare, an ongoing Phase 3 trial of an RSV F vaccine for maternal immunization to protect newborn infants.
Read more at:
https://thefly.com/landingPageNews.php?id=2665398
NVAX the only RSV vaccine in phase 3 trials! With initial positive results! Now I see why they raised the price target to $10
B. Riley FBR analyst George Zavoico raised his price target for Novavax nearly five-fold to $10 after the company announced more details about an informational analysis of Prepare, an ongoing Phase 3 trial of an RSV F vaccine for maternal immunization to protect newborn infants.
Read more at:
https://thefly.com/landingPageNews.php?id=2665398
NVAX the only RSV vaccine in phase 3 trials! With initial positive results! Now I see why they raised the price target to $10
B. Riley FBR analyst George Zavoico raised his price target for Novavax nearly five-fold to $10 after the company announced more details about an informational analysis of Prepare, an ongoing Phase 3 trial of an RSV F vaccine for maternal immunization to protect newborn infants.
Read more at:
https://thefly.com/landingPageNews.php?id=2665398
Indeed, bought initially over $2 been buying when I can. Trying to get my average down, I believe we have a winner here!
I have received my proxy and I have voted, Good luck to all of us who held on for the last 5 years!
Wish I had that many, I have a few thousand, just waiting patiently for the data!
Everyone loading the boat for the next $2 break
Holding strong! Setting up for a great run!
Break 2.35 and I think we could see $3 very quickly
$2+ coming fast!
New high of the day!
When the shorts let this thing go it’s gonna fly
BREAKOUT TIME
VTGN INSTITUTIONS LOADING THE BOAT
“According to the SEC’s latest filings, institutions owning shares of VistaGen Therapeutics, Inc. (:VTGN) have increased their transactions by 135.20%. Institutions now own 26.50% of the company.”
“According to the SEC’s latest filings, institutions owning shares of VistaGen Therapeutics, Inc. (:VTGN) have increased their transactions by 135.20%. Institutions now own 26.50% of the company.”
https://midwaymonitor.com/vistagen-therapeutics-inc-vtgn-is-catching-the-eye-of-institutions/433867/
VTGN has a price target of $30, load the boat, institutional investors loading up themselves
Pre market dip, hope the buyers step in soon
“Taking a broader look brokerage firms’ analysts on the street with an expectant view have Vistagen Therap. Com (NASDAQ:VTGN) high price target of $30 and with a conservative view have low price target of $30.”
Nvax looking beautiful
All the proxy’s I have received came through my broker electronically...
Thanks for the clarification
If someone owns 20,000,000 shares and they are to receive 125% shares of InWith (25,000,000 shares) how will the authorized share count only be 10M?
VTGN GREAT NEWS
SOUTH SAN FRANCISCO, CA--(Marketwired - January 03, 2018) - VistaGen Therapeutics, Inc. (VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AV-101 for development as a potential adjunctive treatment for Major Depressive Disorder (MDD). The FDA's Fast Track process is designed to facilitate the development and review of new treatments for serious conditions with unmet medical need such as MDD.
"Fast Track Designation is another important regulatory milestone for our AV-101 program for MDD, providing us the opportunity for frequent interactions with the FDA focused on the most appropriate and efficient development pathway to bring AV-101 to MDD patients," said Shawn Singh, Chief Executive Officer of VistaGen. "We are on track to dose the first patient in our AV-101 Phase 2 MDD adjunctive treatment study in the first quarter of 2018."
VTGN GREAT NEWS
SOUTH SAN FRANCISCO, CA--(Marketwired - January 03, 2018) - VistaGen Therapeutics, Inc. (VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AV-101 for development as a potential adjunctive treatment for Major Depressive Disorder (MDD). The FDA's Fast Track process is designed to facilitate the development and review of new treatments for serious conditions with unmet medical need such as MDD.
"Fast Track Designation is another important regulatory milestone for our AV-101 program for MDD, providing us the opportunity for frequent interactions with the FDA focused on the most appropriate and efficient development pathway to bring AV-101 to MDD patients," said Shawn Singh, Chief Executive Officer of VistaGen. "We are on track to dose the first patient in our AV-101 Phase 2 MDD adjunctive treatment study in the first quarter of 2018."
Great news!
SOUTH SAN FRANCISCO, CA--(Marketwired - January 03, 2018) - VistaGen Therapeutics, Inc. (VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AV-101 for development as a potential adjunctive treatment for Major Depressive Disorder (MDD). The FDA's Fast Track process is designed to facilitate the development and review of new treatments for serious conditions with unmet medical need such as MDD.
"Fast Track Designation is another important regulatory milestone for our AV-101 program for MDD, providing us the opportunity for frequent interactions with the FDA focused on the most appropriate and efficient development pathway to bring AV-101 to MDD patients," said Shawn Singh, Chief Executive Officer of VistaGen. "We are on track to dose the first patient in our AV-101 Phase 2 MDD adjunctive treatment study in the first quarter of 2018."
It’s not illegal because the new shares are for a private company. Now if they said they were going to buyout EPGL shares at different prices that would be illegal. GLTA
VTGN 1.24 in the after hours, setting up for a strong week ahead!
2018 gonna be an incredible year for biotechs
Someone deleted some good posts. Interesting motives here
NVAX FAST TRACK DESIGNATION
Novavax Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase 1/2 Trial of the NanoFlu™ Vaccine
GlobeNewswire•December 18, 2017
RSV F Vaccine informational analysis completed in fourth quarter of 2017
RSV F Vaccine interim analysis expected mid-2018 with approximately 4,600 enrollees
Filing of RSV F Vaccine BLA anticipated by late 2019
NanoFlu Vaccine data package to be completed and released in February 2018
GAITHERSBURG, Md., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX) today announced the Phase 3 trial of its RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization will continue. Novavax also provided an update on its nanoparticle influenza vaccine candidate with proprietary Matrix-M™ adjuvant (NanoFlu™).
RSV F Vaccine for Infants via Maternal Immunization
“Novavax has completed an informational analysis of our Phase 3 trial of the RSV F Vaccine for infants via maternal immunization using threshold criteria for a commercial product. As a result, we are accelerating our Phase 3 trial enrollment into 2018. Our maternal immunization program is supported by an $89 million grant from the Bill and Melinda Gates Foundation and has also been granted Fast Track designation by the U.S. Food and Drug Administration,” said Stanley C. Erck, President and CEO. “We have enrolled over 3,000 volunteers to date and anticipate that the current pace of enrollment would trigger an interim analysis in mid-2018, with an expected Phase 3 primary endpoint readout in early 2019. This timing would allow us to submit a biologics license application (BLA) by the end of 2019.”
NanoFlu Vaccine
A number of key scientific developments regarding influenza vaccines for the current season have occurred and relate to our NanoFlu program, including:
A November 29, 2017, editorial in the New England Journal of Medicine1 detailed public health concerns related to the poor efficacy of existing seasonal influenza vaccines that is due, in part, to genetic changes or drift in the hemagglutinin (HA) protein, leading to low vaccine efficacy
Based on analyses from the Southern Hemisphere, the effectiveness of the seasonal influenza vaccine was as low as 10% for the A(H3N2) strain2
A November 6, 2017, Proceedings of the National Academy of Sciences3 publication identified that the circulating influenza A(H3N2) virus contains an HA structure that has been lost in the corresponding vaccine strain during adaptation to be grown in eggs (“egg-adapted”) as part of the typical seasonal influenza vaccine manufacturing process, which, in turn, affects vaccine efficacy for egg-based vaccines
Novavax’ NanoFlu vaccine candidate is designed specifically to address these challenges
The wild-type viruses necessary to assess immunogenicity of the vaccines to circulating strains have been difficult to obtain, grow and maintain genetic stability
Therefore, a complete Phase 1/2 data package expected in February 2018
“Recent information published presents both an opportunity and a challenge for our NanoFlu Vaccine program. First, we have the unique opportunity to determine whether our recombinant, adjuvanted NanoFlu vaccine can address egg-adapted virus mismatch. We can also observe whether our vaccine-induced antibodies can neutralize circulating viruses with antigenic drift in humans, as we demonstrated in our ferret study earlier this year,” said Greg Glenn, M.D., President, R&D. “Our team has been able to optimize our assays to address this challenge and we expect to present NanoFlu immunogenicity data that includes HA inhibition and microneutralization assays comparing wild-type virus and egg-based reagents.”
NVAX FAST TRACK DESIGNATION
Novavax Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase 1/2 Trial of the NanoFlu™ Vaccine
GlobeNewswire•December 18, 2017
RSV F Vaccine informational analysis completed in fourth quarter of 2017
RSV F Vaccine interim analysis expected mid-2018 with approximately 4,600 enrollees
Filing of RSV F Vaccine BLA anticipated by late 2019
NanoFlu Vaccine data package to be completed and released in February 2018
GAITHERSBURG, Md., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX) today announced the Phase 3 trial of its RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization will continue. Novavax also provided an update on its nanoparticle influenza vaccine candidate with proprietary Matrix-M™ adjuvant (NanoFlu™).
RSV F Vaccine for Infants via Maternal Immunization
“Novavax has completed an informational analysis of our Phase 3 trial of the RSV F Vaccine for infants via maternal immunization using threshold criteria for a commercial product. As a result, we are accelerating our Phase 3 trial enrollment into 2018. Our maternal immunization program is supported by an $89 million grant from the Bill and Melinda Gates Foundation and has also been granted Fast Track designation by the U.S. Food and Drug Administration,” said Stanley C. Erck, President and CEO. “We have enrolled over 3,000 volunteers to date and anticipate that the current pace of enrollment would trigger an interim analysis in mid-2018, with an expected Phase 3 primary endpoint readout in early 2019. This timing would allow us to submit a biologics license application (BLA) by the end of 2019.”
NanoFlu Vaccine
A number of key scientific developments regarding influenza vaccines for the current season have occurred and relate to our NanoFlu program, including:
A November 29, 2017, editorial in the New England Journal of Medicine1 detailed public health concerns related to the poor efficacy of existing seasonal influenza vaccines that is due, in part, to genetic changes or drift in the hemagglutinin (HA) protein, leading to low vaccine efficacy
Based on analyses from the Southern Hemisphere, the effectiveness of the seasonal influenza vaccine was as low as 10% for the A(H3N2) strain2
A November 6, 2017, Proceedings of the National Academy of Sciences3 publication identified that the circulating influenza A(H3N2) virus contains an HA structure that has been lost in the corresponding vaccine strain during adaptation to be grown in eggs (“egg-adapted”) as part of the typical seasonal influenza vaccine manufacturing process, which, in turn, affects vaccine efficacy for egg-based vaccines
Novavax’ NanoFlu vaccine candidate is designed specifically to address these challenges
The wild-type viruses necessary to assess immunogenicity of the vaccines to circulating strains have been difficult to obtain, grow and maintain genetic stability
Therefore, a complete Phase 1/2 data package expected in February 2018
“Recent information published presents both an opportunity and a challenge for our NanoFlu Vaccine program. First, we have the unique opportunity to determine whether our recombinant, adjuvanted NanoFlu vaccine can address egg-adapted virus mismatch. We can also observe whether our vaccine-induced antibodies can neutralize circulating viruses with antigenic drift in humans, as we demonstrated in our ferret study earlier this year,” said Greg Glenn, M.D., President, R&D. “Our team has been able to optimize our assays to address this challenge and we expect to present NanoFlu immunogenicity data that includes HA inhibition and microneutralization assays comparing wild-type virus and egg-based reagents.”
NVAX Fast Track Designation
Novavax Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase 1/2 Trial of the NanoFlu™ Vaccine
GlobeNewswire•December 18, 2017
RSV F Vaccine informational analysis completed in fourth quarter of 2017
RSV F Vaccine interim analysis expected mid-2018 with approximately 4,600 enrollees
Filing of RSV F Vaccine BLA anticipated by late 2019
NanoFlu Vaccine data package to be completed and released in February 2018
GAITHERSBURG, Md., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX) today announced the Phase 3 trial of its RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization will continue. Novavax also provided an update on its nanoparticle influenza vaccine candidate with proprietary Matrix-M™ adjuvant (NanoFlu™).
RSV F Vaccine for Infants via Maternal Immunization
“Novavax has completed an informational analysis of our Phase 3 trial of the RSV F Vaccine for infants via maternal immunization using threshold criteria for a commercial product. As a result, we are accelerating our Phase 3 trial enrollment into 2018. Our maternal immunization program is supported by an $89 million grant from the Bill and Melinda Gates Foundation and has also been granted Fast Track designation by the U.S. Food and Drug Administration,” said Stanley C. Erck, President and CEO. “We have enrolled over 3,000 volunteers to date and anticipate that the current pace of enrollment would trigger an interim analysis in mid-2018, with an expected Phase 3 primary endpoint readout in early 2019. This timing would allow us to submit a biologics license application (BLA) by the end of 2019.”
NanoFlu Vaccine
A number of key scientific developments regarding influenza vaccines for the current season have occurred and relate to our NanoFlu program, including:
A November 29, 2017, editorial in the New England Journal of Medicine1 detailed public health concerns related to the poor efficacy of existing seasonal influenza vaccines that is due, in part, to genetic changes or drift in the hemagglutinin (HA) protein, leading to low vaccine efficacy
Based on analyses from the Southern Hemisphere, the effectiveness of the seasonal influenza vaccine was as low as 10% for the A(H3N2) strain2
A November 6, 2017, Proceedings of the National Academy of Sciences3 publication identified that the circulating influenza A(H3N2) virus contains an HA structure that has been lost in the corresponding vaccine strain during adaptation to be grown in eggs (“egg-adapted”) as part of the typical seasonal influenza vaccine manufacturing process, which, in turn, affects vaccine efficacy for egg-based vaccines
Novavax’ NanoFlu vaccine candidate is designed specifically to address these challenges
The wild-type viruses necessary to assess immunogenicity of the vaccines to circulating strains have been difficult to obtain, grow and maintain genetic stability
Therefore, a complete Phase 1/2 data package expected in February 2018
“Recent information published presents both an opportunity and a challenge for our NanoFlu Vaccine program. First, we have the unique opportunity to determine whether our recombinant, adjuvanted NanoFlu vaccine can address egg-adapted virus mismatch. We can also observe whether our vaccine-induced antibodies can neutralize circulating viruses with antigenic drift in humans, as we demonstrated in our ferret study earlier this year,” said Greg Glenn, M.D., President, R&D. “Our team has been able to optimize our assays to address this challenge and we expect to present NanoFlu immunogenicity data that includes HA inhibition and microneutralization assays comparing wild-type virus and egg-based reagents.”
About RSV
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections and the leading viral cause of severe lower respiratory tract disease in infants and young children worldwide, with estimated annual infection and mortality rates of 64 million and 160,000, respectively4. In the US, RSV is the leading cause of hospitalization of infants5. Despite the induction of post-infection immunity, repeat infection and lifelong susceptibility to RSV is common6,7. Currently, there is no approved RSV vaccine available.
About Influenza
Influenza is a world-wide infectious disease that causes illness in humans with symptoms ranging from mild to life-threatening or even death. Serious illness occurs not only in susceptible populations such as pediatrics and older adults, but also in the general population largely because of infection by unique strains of influenza for which most humans have not developed protective antibodies. An estimated one million deaths each year are attributed to influenza8. Current estimates for seasonal influenza vaccine growth in the top seven markets (U.S., Japan, France, Germany, Italy, Spain and UK), show a potential increase from approximately $3.2 billion in the 2012-2013 season to $5.3 billion by the 2021-2022 season9.
About Fast Track
The Fast Track Drug Development Program was established under the FDA Modernization Act of 1997. A Fast Track designation is intended for products that treat serious or life-threatening diseases or conditions, and that demonstrate the potential to address unmet medical needs for such diseases or conditions. The program is intended to facilitate development and expedite review of drugs to treat serious and life-threatening conditions so that an approved product can reach the market expeditiously. Specifically, Fast Track designation facilitates meetings to discuss all aspects of development to support licensure and it provides the opportunity to submit sections of a Biologics License Application (BLA) on a rolling basis as data become available, which permits the FDA to review modules of the BLA as they are received instead of waiting for the entire BLA submission. In addition, priority review (6 month review versus standard 10 month review) is a potential benefit that may be available to Novavax’ RSV F vaccine in the future.
About Novavax
Novavax, Inc. (NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
NVAX Fast track designation
Novavax Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase 1/2 Trial of the NanoFlu™ Vaccine
GlobeNewswire•December 18, 2017
RSV F Vaccine informational analysis completed in fourth quarter of 2017
RSV F Vaccine interim analysis expected mid-2018 with approximately 4,600 enrollees
Filing of RSV F Vaccine BLA anticipated by late 2019
NanoFlu Vaccine data package to be completed and released in February 2018
GAITHERSBURG, Md., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX) today announced the Phase 3 trial of its RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization will continue. Novavax also provided an update on its nanoparticle influenza vaccine candidate with proprietary Matrix-M™ adjuvant (NanoFlu™).
RSV F Vaccine for Infants via Maternal Immunization
“Novavax has completed an informational analysis of our Phase 3 trial of the RSV F Vaccine for infants via maternal immunization using threshold criteria for a commercial product. As a result, we are accelerating our Phase 3 trial enrollment into 2018. Our maternal immunization program is supported by an $89 million grant from the Bill and Melinda Gates Foundation and has also been granted Fast Track designation by the U.S. Food and Drug Administration,” said Stanley C. Erck, President and CEO. “We have enrolled over 3,000 volunteers to date and anticipate that the current pace of enrollment would trigger an interim analysis in mid-2018, with an expected Phase 3 primary endpoint readout in early 2019. This timing would allow us to submit a biologics license application (BLA) by the end of 2019.”
NanoFlu Vaccine
A number of key scientific developments regarding influenza vaccines for the current season have occurred and relate to our NanoFlu program, including:
A November 29, 2017, editorial in the New England Journal of Medicine1 detailed public health concerns related to the poor efficacy of existing seasonal influenza vaccines that is due, in part, to genetic changes or drift in the hemagglutinin (HA) protein, leading to low vaccine efficacy
Based on analyses from the Southern Hemisphere, the effectiveness of the seasonal influenza vaccine was as low as 10% for the A(H3N2) strain2
A November 6, 2017, Proceedings of the National Academy of Sciences3 publication identified that the circulating influenza A(H3N2) virus contains an HA structure that has been lost in the corresponding vaccine strain during adaptation to be grown in eggs (“egg-adapted”) as part of the typical seasonal influenza vaccine manufacturing process, which, in turn, affects vaccine efficacy for egg-based vaccines
Novavax’ NanoFlu vaccine candidate is designed specifically to address these challenges
The wild-type viruses necessary to assess immunogenicity of the vaccines to circulating strains have been difficult to obtain, grow and maintain genetic stability
Therefore, a complete Phase 1/2 data package expected in February 2018
“Recent information published presents both an opportunity and a challenge for our NanoFlu Vaccine program. First, we have the unique opportunity to determine whether our recombinant, adjuvanted NanoFlu vaccine can address egg-adapted virus mismatch. We can also observe whether our vaccine-induced antibodies can neutralize circulating viruses with antigenic drift in humans, as we demonstrated in our ferret study earlier this year,” said Greg Glenn, M.D., President, R&D. “Our team has been able to optimize our assays to address this challenge and we expect to present NanoFlu immunogenicity data that includes HA inhibition and microneutralization assays comparing wild-type virus and egg-based reagents.”
About RSV
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections and the leading viral cause of severe lower respiratory tract disease in infants and young children worldwide, with estimated annual infection and mortality rates of 64 million and 160,000, respectively4. In the US, RSV is the leading cause of hospitalization of infants5. Despite the induction of post-infection immunity, repeat infection and lifelong susceptibility to RSV is common6,7. Currently, there is no approved RSV vaccine available.
About Influenza
Influenza is a world-wide infectious disease that causes illness in humans with symptoms ranging from mild to life-threatening or even death. Serious illness occurs not only in susceptible populations such as pediatrics and older adults, but also in the general population largely because of infection by unique strains of influenza for which most humans have not developed protective antibodies. An estimated one million deaths each year are attributed to influenza8. Current estimates for seasonal influenza vaccine growth in the top seven markets (U.S., Japan, France, Germany, Italy, Spain and UK), show a potential increase from approximately $3.2 billion in the 2012-2013 season to $5.3 billion by the 2021-2022 season9.
About Fast Track
The Fast Track Drug Development Program was established under the FDA Modernization Act of 1997. A Fast Track designation is intended for products that treat serious or life-threatening diseases or conditions, and that demonstrate the potential to address unmet medical needs for such diseases or conditions. The program is intended to facilitate development and expedite review of drugs to treat serious and life-threatening conditions so that an approved product can reach the market expeditiously. Specifically, Fast Track designation facilitates meetings to discuss all aspects of development to support licensure and it provides the opportunity to submit sections of a Biologics License Application (BLA) on a rolling basis as data become available, which permits the FDA to review modules of the BLA as they are received instead of waiting for the entire BLA submission. In addition, priority review (6 month review versus standard 10 month review) is a potential benefit that may be available to Novavax’ RSV F vaccine in the future.
About Novavax
Novavax, Inc. (NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.